Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Feb;32(2):171-182.
doi: 10.1016/j.annonc.2020.11.003. Epub 2020 Nov 24.

Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up

P Roth  1 , A Pace  2 , E Le Rhun  3 , M Weller  1 , C Ay  4 , E Cohen-Jonathan Moyal  5 , M Coomans  6 , R Giusti  7 , K Jordan  8 , R Nishikawa  9 , F Winkler  10 , J T Hong  11 , R Ruda  12 , S Villà  13 , M J B Taphoorn  14 , W Wick  15 , M Preusser  16 ; EANO Executive Board. Electronic address: office@eano.eu; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Affiliations
Free article
Practice Guideline

Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up

P Roth et al. Ann Oncol. 2021 Feb.
Free article
No abstract available

Keywords: brain metastasis; brain tumour; complications; oedema; seizures; thrombosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure PR has received honoraria for lectures or advisory board participation from Bristol-Myers Squibb, Covagen, Debiopharm, Merck Sharp and Dohme, Novocure, QED and Virometix and research support from Merck Sharp and Dohme; AP has received honoraria for advisory board participation from AbbVie; ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from AbbVie, Daiichi Sankyo, Mundipharma and Novartis; MW has received research grants from AbbVie, Adastra Pharmaceuticals, Bayer, Merck, Sharp and Dohme, Merck (EMD), Novocure, OGD2 Pharma, PIQUR Therapeutics and Roche and honoraria for lectures or advisory board participation or consulting from AbbVie, Bristol-Myers Squibb, Celgene, Merck, Sharp and Dohme, Merck (EMD), Novocure, Orbus, Pfizer, Progenics, Roche and Tocagen; CA has received honoraria for lectures, consultancy or advisory board participation from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Pfizer and Sanofi; EC-JM has reported advisory board and/or has received honoraria from Merck Serono, Accuray and Brainlab and research grants from Merck Serono and AstraZeneca; RG has received honoraria for lectures, consultancy or advisory board participation from Kiowa Kirin, Angelini Pharma, Bristol-Myers Squibb, Boehringer Ingelheim, Merck, Sharp and Dohme, Roche and AstraZeneca; KJ has reported advisory board and/or honoraria for presentations for Merck, Sharp and Dohme, Helsinn, Tesaro, Amgen, Hexal, Pfizer, Voluntis and Kreussler Pharma; RN has received research support from Merck, Sharp and Dohme, Chugai and Eisai and honoraria for lectures, consultancy or advisory board participation from Chugai, Eisai, ONO, AbbVie, Daiichi Sankyo and Novocure; RR has received honoraria for lectures or advisory board participation from UCB and Novocure; MP has received research support from Böehringer Ingelheim, GlaxoSmithKline, Merck, Sharp and Dohme and Roche and honoraria for lectures, consultancy or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca, AbbVie, Lilly, MEDahead, Daiichi Sankyo and Merck, Sharp and Dohme; MC, FW, SV, MJBT, YKH and WW have declared no conflicts of interest.

Comment in

Publication types

LinkOut - more resources